Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.

Proteasome-regulated NF-κB has been shown to be important for cell survival in T-cell lymphoma and Hodgkin lymphoma models. Several new small-molecule proteasome inhibitors are under various stages of active preclinical and clinical development. We completed a comprehensive preclinical examination of the efficacy and associated biologic effects of a second-generation proteasome inhibitor, ixazomib, in T-cell lymphoma and Hodgkin lymphoma cells and in vivo SCID mouse models. We demonstrated that ixazomib induced potent cell death in all cell lines at clinically achievable concentrations. In addition, it significantly inhibited tumor growth and improved survival in T-cell lymphoma and Hodgkin lymphoma human lymphoma xenograft models. Through global transcriptome analyses, proteasomal inhibition showed conserved overlap in downregulation of cell cycle, chromatin modification, and DNA repair processes in ixazomib-sensitive lymphoma cells. The predicted activity for tumor suppressors and oncogenes, the impact on "hallmarks of cancer," and the analysis of key significant genes from global transcriptome analysis for ixazomib strongly favored tumor inhibition via downregulation of MYC and CHK1, its target genes. Furthermore, in ixazomib-treated lymphoma cells, we identified that CHK1 was involved in the regulation of MYC expression through chromatin modification involving histone H3 acetylation via chromatin immunoprecipitation. Finally, using pharmacologic and RNA silencing of CHK1 or the associated MYC-related mechanism, we demonstrated synergistic cell death in combination with antiproteasome therapy. Altogether, ixazomib significantly downregulates MYC and induces potent cell death in T-cell lymphoma and Hodgkin lymphoma, and we identified that combinatorial therapy with anti-CHK1 treatment represents a rational and novel therapeutic approach. Cancer Res; 76(11); 3319-31. ©2016 AACR.

[1]  Y. Takatsuka,et al.  A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma , 2015, Cancer science.

[2]  Xin A. Zhang,et al.  MYC-mediated synthetic lethality for treatment of hematological malignancies. , 2015, Current cancer drug targets.

[3]  Philip Hahnfeldt,et al.  Host age is a systemic regulator of gene expression impacting cancer progression. , 2015, Cancer research.

[4]  D. Neuberg,et al.  The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks , 2015, Cancer informatics.

[5]  A. Evens,et al.  The Novel Organic Arsenical Darinaparsin Induces MAPK-Mediated and SHP1-Dependent Cell Death in T-cell Lymphoma and Hodgkin Lymphoma Cells and Human Xenograft Models , 2014, Clinical Cancer Research.

[6]  B. Cheson,et al.  Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma , 2014, Blood Cancer Journal.

[7]  M. McKeown,et al.  Therapeutic strategies to inhibit MYC. , 2014, Cold Spring Harbor perspectives in medicine.

[8]  B. Coiffier,et al.  Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. , 2014, Cancer treatment reviews.

[9]  E. Campo,et al.  Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma , 2014, Leukemia.

[10]  N. Sekiguchi,et al.  The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy , 2014, International Journal of Hematology.

[11]  V. Dötsch,et al.  Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. , 2014, Molecular cell.

[12]  Sonali M. Smith,et al.  A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T‐cell lymphomas , 2013, British journal of haematology.

[13]  E. Wanker,et al.  Myc inhibition impairs autophagosome formation , 2013, Human molecular genetics.

[14]  W. Wong,et al.  MYC Degradation under Low O2 Tension Promotes Survival by Evading Hypoxia-Induced Cell Death , 2013, Molecular and Cellular Biology.

[15]  P. Hahnfeldt,et al.  Age and Space Irradiation Modulate Tumor Progression: Implications for Carcinogenesis Risk , 2013, Radiation research.

[16]  K. Aldape,et al.  PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis , 2012, Cell.

[17]  Maria Thanasoula,et al.  ATM/ATR checkpoint activation downregulates CDC25C to prevent mitotic entry with uncapped telomeres , 2012, The EMBO journal.

[18]  Michele Cavo,et al.  Proteasome inhibitors in multiple myeloma: 10 years later. , 2012, Blood.

[19]  G. Mulligan,et al.  An historic perspective of proteasome inhibition. , 2012, Seminars in hematology.

[20]  C. Kirk.  Discovery and development of second-generation proteasome inhibitors. , 2012, Seminars in hematology.

[21]  J. Gribben,et al.  Blocking Autophagy Prevents Bortezomib-Induced NF-κB Activation by Reducing I-κBα Degradation in Lymphoma Cells , 2012, PloS one.

[22]  M. Barbacid,et al.  Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.

[23]  K. Anderson,et al.  Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma , 2011, Molecular Cancer Therapeutics.

[24]  Ulrich Keller,et al.  Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells , 2011, Clinical Cancer Research.

[25]  A. Berger,et al.  Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies , 2011, Clinical Cancer Research.

[26]  O. Olopade,et al.  c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells , 2011, BMC Cancer.

[27]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[28]  Di Chen,et al.  Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. , 2011, Current cancer drug targets.

[29]  Gary D Bader,et al.  Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.

[30]  T. Wirth,et al.  Advances in the understanding of MYC‐induced lymphomagenesis , 2010, British journal of haematology.

[31]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[32]  B. Thimmapaya,et al.  c-Myc-induced Aberrant DNA Synthesis and Activation of DNA Damage Response in p300 Knockdown Cells* , 2009, Journal of Biological Chemistry.

[33]  G. Mundy,et al.  Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo , 2009, American journal of hematology.

[34]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[35]  V. Diehl,et al.  Treatment of Hodgkin lymphoma: the past, present, and future , 2008, Nature Clinical Practice Oncology.

[36]  J. Inazawa,et al.  Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. , 2008, Blood.

[37]  Makoto Nakanishi,et al.  Chk1 Is a Histone H3 Threonine 11 Kinase that Regulates DNA Damage-Induced Transcriptional Repression , 2008, Cell.

[38]  S. Pileri,et al.  Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Taniguchi,et al.  Proteasome function is required for DNA damage response and fanconi anemia pathway activation. , 2007, Cancer research.

[40]  B. Cheson,et al.  Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206 , 2007, Leukemia & lymphoma.

[41]  H. Stein,et al.  Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas , 2005 .

[42]  Gordon K. Smyth,et al.  Use of within-array replicate spots for assessing differential expression in microarray experiments , 2005, Bioinform..

[43]  K. Elenitoba-Johnson,et al.  Ubiquitin Ligases in Malignant Lymphoma , 2004, Leukemia & lymphoma.

[44]  B. Thimmapaya,et al.  Repression of c-Myc and inhibition of G1 exit in cells conditionally overexpressing p300 that is not dependent on its histone acetyltransferase activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[46]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[47]  B. Dörken,et al.  Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. , 2001, Blood.

[48]  P. Picci,et al.  C-myc and c-fos in Human Osteosarcoma: Prognostic Value of mRNA and Protein Expression , 1998, Oncology.

[49]  R. Hay,et al.  Defective IκBα in Hodgkin cell lines with constitutively active NF-κB , 1998, Oncogene.

[50]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[51]  B. Dörken,et al.  High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. , 1996, Blood.

[52]  R. Küppers.  Molecular biology of Hodgkin lymphoma. , 2009, Hematology. American Society of Hematology. Education Program.